Novel agents in first-line therapy for myeloma: From the Multiple Myeloma Research Foundation

ONCOLOGY

Volumn 19, Issue 12, 2005, Pages 1551-1554

  Jagannath, Sundar ^a  

^a ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DISEASE COURSE; HUMAN; MONOTHERAPY; MULTIPLE MYELOMA; BLOOD EXAMINATION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HOSPITALIZATION; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; RISK ASSESSMENT; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC TESTS; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MULTIPLE MYELOMA; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 33644856879     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Dhodapkar MV, Singh J, Mehta J, et al: Antimyeloma activity of pamidronate in vivo. Br J Haematol 103:530-532, 1998.
2. Durie BG, Salmon SE: A clinical staging system for multiple myeloma. Cancer 36:842-854, 1975.
3. Gregory WM, Richards MA, Malpas JS, et al: Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: An overview of published trials. J Clin Oncol 10:334-342, 1992.
4. Hjorth M, Hellquist L, Holmberg E, et al: Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I: A randomized study. Myeloma Group of Western Sweden. Eur J Haematol 50:95-102, 1993.
5. International Myeloma Working Group: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 121:749-757, 2003.
6. Jagannath S, Durie J, Wolf E, et al: First-line therapy with bortezomib in patients with multiple myeloma (abstract 6551). Proc Am Soc Clin Oncol 23:568, 2004.
7. Kyle RA: Long-term survival in multiple myeloma. N Engl J Med 308:314-316, 1983.
8. Ludwig H, Fritz E, Kotzmann H, et al: Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322:1693-1699, 1990.
9. Rajkumar SV, Dispenzieri A, Fonseca R, et al: Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 15:1274-1276, 2001.
10. Rajkumar SV, Hayman S, Gertz MA, et al: Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20:4319-4323, 2002.
11. Richardson PG, Barlogie B, Berenson J, et al: A phase II study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003.
12. Weber D, Rankin K, Gavino M, et al: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21:16-19, 2003.